<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197637</url>
  </required_header>
  <id_info>
    <org_study_id>OVIMA-1210</org_study_id>
    <secondary_id>2013-001625-12</secondary_id>
    <secondary_id>PHRC 12- 194</secondary_id>
    <nct_id>NCT02197637</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma</brief_title>
  <acronym>OVIMA-1210</acronym>
  <official_title>Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral vinorelbine is effective in the&#xD;
      treatment of children with progressive or recurrent unresectable low grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine efficacy of oral vinorelbine in children with&#xD;
      progressive or recurrent unresectable low grade glioma, in addition to safety,&#xD;
      pharmacokinetic, pharmacogenetic, medical costs and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>9 months</time_frame>
    <description>no progressive disease according to RANO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Complete, partial and minor responses according to RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Complete, partial and minor responses according to RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival PFS</measure>
    <time_frame>36 months</time_frame>
    <description>No progressive disease according to RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival OS</measure>
    <time_frame>36 months</time_frame>
    <description>Death incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Modulation Index GMI</measure>
    <time_frame>36 months</time_frame>
    <description>GMI defined as PFS2/ PSF1 ratio (PFS2 = PFS since the beginning of study treatment ; PFS1 = PFS observed in previous line of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>According to NCI-CTC AE scale v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifications of tumor aspects in diffusion and perfusion MRI</measure>
    <time_frame>At each tumor assessment, after 3, 6, 9 and 12 cycles of treatment, at the end of study, then every 4 months during the first year post therapy, then every 6 months for 3 years, if no prior progressive disease</time_frame>
    <description>Cerebral and/or spinal MRI (morphological and functional) with 2 dimensional assessment of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constitutional polymorphisms of cyp3A5, ABCB1</measure>
    <time_frame>Before the start of treatment</time_frame>
    <description>Single nucleotide polymorphisms (SNPs) will be analyzed by real time PCR and correlated with efficacy and toxicity of vinorelbine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>cycles 1 and 2, prior to the initial dose, 30 min, 1, 1.5, 2, 3, 6, 8, 10 and 26 hours post-dose</time_frame>
    <description>Plasmatic concentrations measured by LC-MS/MS (liquid chromatography tandem mass spectrometry) ; Area under the curve (AUC), maximal concentration (Cmax), time to Cmax (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical costs</measure>
    <time_frame>during all the study (up to 1 year)</time_frame>
    <description>Costs of medical care including : hospitalisations, emergency admissions, nursing care at home, medical consultations, diet support...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Utilities Index (HUI)</measure>
    <time_frame>Before the treatment, then at day 1 of 1st cycle, after the 3th, 6th, 9th and the 12th cycles of study treatment, and at the end of study (up to 1 year)</time_frame>
    <description>Health Utilities Index (HUI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Low-Grade Glioma</condition>
  <arm_group>
    <arm_group_label>ORAL VINORELBINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORAL VINORELBINE</intervention_name>
    <description>Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.</description>
    <arm_group_label>ORAL VINORELBINE</arm_group_label>
    <other_name>NAVELBINE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        TUMOR CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or progressive primary Low-Grade Glioma (LGG)&#xD;
             defined as follow (WHO classification 2007): optic pathway glioma (OPG), pilocytic&#xD;
             astrocytoma (PA), fibrillary or diffuse astrocytoma (DA), oligodendroglioma (OG) or&#xD;
             oligoastrocytoma (OA)&#xD;
&#xD;
          -  Patients with OPG do not require biopsy confirmation of disease, if clinical and&#xD;
             radiological findings as well as ophthalmological examination are unequivocal&#xD;
&#xD;
          -  Low-Grade Glioma involving the brainstem can be included in case of histological&#xD;
             confirmation&#xD;
&#xD;
          -  Tumor has to be considered as non totally resectable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age 6-18 years old&#xD;
&#xD;
          -  Lansky or Karnofsky status more than 50 %&#xD;
&#xD;
          -  Measurable disease on cerebral and/or spinal MRI, with at least 1 lesion diameter&#xD;
             superior to 1 cm&#xD;
&#xD;
          -  Patients with metastatic disease are eligible, but at least 1 lesion must be&#xD;
             measurable as previously defined&#xD;
&#xD;
          -  Patients must have received at least 1 prior chemotherapy regimen containing&#xD;
             carboplatin&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Evidence of adequate organ functions, including:&#xD;
&#xD;
          -  neutrophil count (ANC) ≥ 1500/mm3 ,&#xD;
&#xD;
          -  platelet count ≥100 000/mm3 ;&#xD;
&#xD;
          -  serum creatinine &lt; 1.5 x normal for age when the serum creatinine is ≥ 1.5 × the ULN,&#xD;
             the glomerular filtration rate (either estimated or formal) must be &gt; 70&#xD;
             mL/min/1.73m2;&#xD;
&#xD;
          -  total bilirubin&lt; 1.5 x normal for age,&#xD;
&#xD;
          -  ASAT and ALAT &lt; 2.5 x normal for age&#xD;
&#xD;
          -  Effective contraception for patients (male and female) with reproductive potential,&#xD;
             and for a minimum of 3 months after the end of treatment&#xD;
&#xD;
          -  Negative pregnancy test, if applicable&#xD;
&#xD;
          -  Patients able to swallow capsules&#xD;
&#xD;
          -  Patient affiliated with a health insurance system&#xD;
&#xD;
          -  Written informed consent of patient and/or parents/guardians prior to the study&#xD;
             participation.&#xD;
&#xD;
        PRIOR OR CONCURRENT THERAPY&#xD;
&#xD;
          -  Prior treatments containing vinca alkaloids like vincristine and/or vinblastine are&#xD;
             authorized&#xD;
&#xD;
          -  Patients must have fully recovered from the toxic effects of any prior therapy before&#xD;
             entering the study. No organ toxicity superior to grade 2 according to NCI-CTCAE v4.0&#xD;
&#xD;
          -  An interval of at least 2 months from prior radiotherapy, 6 weeks from nitrosourea&#xD;
             chemotherapy, and 4 weeks from other chemotherapy regimen, is required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria failure&#xD;
&#xD;
          -  Prior treatment with intravenous or oral vinorelbine&#xD;
&#xD;
          -  Known hypersensibility to other vinca-alkaloïdes&#xD;
&#xD;
          -  Digestive pathology affecting absorption in a important way&#xD;
&#xD;
          -  Prior surgical resection of stomach or the small intestine&#xD;
&#xD;
          -  Severe hepatic failure independent from tumoral disease&#xD;
&#xD;
          -  Fructose intolerance&#xD;
&#xD;
          -  Leptomeningeal relapse without any available measurable disease on MRI (for example,&#xD;
             leptomeningeal relapse with totally resected primary lesion)&#xD;
&#xD;
          -  Uncontrolled active infection within 2 weeks&#xD;
&#xD;
          -  Pregnancy or breast feeding woman&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or active infection&#xD;
&#xD;
          -  Unsuitable for medical follow-up (geographic, social or mental reasons)&#xD;
&#xD;
          -  Patients requiring long-term oxygen therapy&#xD;
&#xD;
          -  Patients with ANC less than 1500/mm3&#xD;
&#xD;
          -  Patients vaccinated against yellow fever&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre LEBLOND, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret, Lille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas ANDRE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital La Timone, Marseille, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

